• 1
    McGregor B, Tulloch AGS, Quinlan MF et al. The role of bone scanning in the assessment of prostatic carcinoma. Br J Urol 1978; 50: 17881
  • 2
    Gerber G, Chodak GW. Assessment of value of routine bone scans in patients with newly diagnosed prostate cancer. Urology 1991; 37: 41822
  • 3
    Schaffer DL, Pendergrass HP. Comparison of enzyme, clinical, radiographic and radionuclide methods of detecting bone metastases from carcinoma of the prostate. Radiology 1976; 121: 4314
  • 4
    Oesterling JE, Martin SK, Bergstralh EJ et al. The use of prostate specific antigen in staging patients with newly diagnosed prostate cancer. JAMA 1993; 269: 5760
  • 5
    Kemp PM, Maguire GA, Bird NJ. Which patients with prostate carcinoma require a staging bone scan? Br J Urol 1997; 79: 6114
  • 6
    Levran A, Gonzalez JA, Diokno AC et al. Are pelvic computed tomography, bone scan and pelvic lymphadenectomy necessary in the staging of prostatic cancer? Br J Urol 1995; 75: 77881
  • 7
    Rudoni M, Antonini G, Favro M et al. The clinical value of prostate-specific antigen and bone scintigraphy in the staging of patients with newly diagnosed, pathologically proven prostate cancer. Eur J Nucl Med 1995; 22: 20711
  • 8
    Chybowski FM, Keller JJ, Bergstralh EJ et al. Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: Prostate specific antigen is superior to all other clinical parameters. J Urol 1991; 145: 3138
  • 9
    Gleave ME, Coupland D, Drachenberg D et al. Ability of serum prostate-specific antigen levels to predict normal bone scans in patients with newly diagnosed prostate cancer. Urology 1996; 47: 70812
  • 10
    Choo R, Klotz L, Danjoux C et al. Feasibility study. Watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on PSA, histological and/or clinical progression. J Urol 2002; 167: 16649
  • 11
    Choo R, DeBoer G, Klotz L et al. PSA doubling time of prostate carcinoma managed with watchful observation alone. Int J Radiat Oncol Biol Phys 2001; 50: 61520
  • 12
    Lehr JE, Pienta KJ. Preferential adhesion of prostate cancer cells to a human bone marrow endothelial cell line. JNCI 1998; 90: 11823
  • 13
    Murphy GP, Natarajan N, Pontes JE et al. The national survey of prostate cancer in the United States by the American College of Surgeons. J Urol 1982; 127: 92834
  • 14
    Veterans Administration Cooperative Urologic Research Group. Treatment and survival of patients with cancer of the prostate. Surg Gynecol Obstet 1967; 124: 10117
  • 15
    Boring CC, Squires TS, Tong T, Montgomery S. Cancer statistics, 1994. CA Cancer J Clin 1994; 44: 726
  • 16
    Brawer MK, Chemer MP, Beatie J, Buchner DM, Vessella RL, Lange PH. Screening for prostatic carcinoma with prostate specific antigen. J Urol 1992; 147: 8415
  • 17
    Catalona WJ, Smith DS, Ratliff TL et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. New Eng J Med 1991; 324: 115661
  • 18
    Wymenga LFA, Boomsma JHB, Groenier K et al. Routine bone scans in patients with prostate cancer related to serum prostate-specific antigen and alkaline phosphatase. BJU Int 2001; 88: 22630
  • 19
    Medical Research Council Prostate Cancer Working Party Investigators Working Group. Immediate versus deferred treatment for advanced prostate cancer: initial results of the Medical Research Council trial. Br J Urol 1997; 79: 235 46
  • 20
    Chodak GW, Thisted RA, Gerber GS et al. Results of conservative management of clinically localized prostate cancer. New Eng J Med 1994; 330: 2428
  • 21
    Oesterling JE. Using prostate-specific antigen to eliminate unnecessary diagnostic tests: significant worldwide economic implications. Urology 1995; 46 (Suppl. 3A): 2633